All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-08-02T14:13:20.000Z

FDA grants Idhifa® (enasidenib) approval for the treatment of R/R AML patients with IDH2 mutation

Aug 2, 2017
Share:

Bookmark this article

On 1st August 2017, the U.S. Food and Drug Administration (FDA) granted approval to Idhifa® (enasidenib) for the treatment of adult patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) with an Isocitrate Dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.1 The approval comes after the priority review designation granted to enasidenib in March 2017, which was reported here.

This approval for enasidenib, a first in class, oral, selective inhibitor of mutations in IDH2, was based on results from the phase I/II AG-221 AML-001 study (NCT01915498). In this study, the efficacy of enasidenib, was assessed in R/R AML patients (median age = 68 years) with mutant IDH2. Patients were orally administered enasidenib at a starting dose of 100 mg daily until disease progression or unacceptable toxicity. The key results were:

  • Complete Response/ Complete Response with Partial Hematologic Improvement (CR/CRh); 23%

The safety of enasidenib was also assessed in 214 R/R IDH2 mutated AML patients in this study. The key results were:

  • 30-day and 60-day mortality rates were 4.2% (9/214) and 11.7% (25/214) respectively
  • Adverse Events (AEs) included indirect hyperbilirubinemia and IDH-inhibitor-associated differentiation syndrome (14%)

In summary, enasidenib was well-tolerated and induced hematologic responses in mutant IDH2 R/R AML patients.2 More results from this phase I/II AG-221 AML-001 study are reported here.

Idhifa® was approved alongside the Abbott RealTime™ IDH2 companion diagnostic test, which is FDA-approved as an aid in identifying IDH2 mutated AML patients for treatment with Idhifa®.

  1. Celgene: FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation. 2017 Aug 1.http://ir.celgene.com/releasedetail.cfm?ReleaseID=1035377&utm_source=Social&utm_medium=Twitter&utm_campaign=AML&utm_content=FDA%20Approval_PR [Accessed 2017 Aug 1].
  2. Stein E. M. et al. Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 June 6. DOI: 10.1182/blood-2017-04-779405. [Epub ahead of print].

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox